Dr. Dholaria's clinical interests include non-Hodgkin lymphoma, multiple myeloma, acute and chronic leukemias, adoptive cellular therapy (CAR-T), and stem cell transplantation. He is board certified in Internal Medicine, Hematology and Oncology. His primary field of research is in the use of adoptive cellular therapies for the treatment of relapsed lymphoid and plasma cell malignancies. He has conducted studies investigating the outcomes of non-Hodgkin lymphoma patients undergoing chimeric antigen receptor T-cell (CAR-T) therapies. He is involved in translational research investigating the biomarkers of CAR T-cell therapy associated toxicities. He has also conducted several observational studies utilizing cancer registries to study the outcomes of leukemia and lymphoma patients undergoing allogenic stem cell transplantation and presented his findings in national meetings.